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This report examines the impact of graft composition on
outcomes in 130 patients with hematological malignancies
given unrelated donor granulocyte-colony-stimulating-factor-
mobilized peripheral blood mononuclear cells (G-PBMC)
(n¼ 116) or marrow (n¼ 14) transplantation after nonmyeloa-
blative conditioning with 90 mg/m2 fludarabine and 2 Gy TBI.
The median number of CD34þ cells transplanted was 6.5106/
kg. Higher numbers of grafted CD14þ (P¼0.0008), CD3þ
(P¼0.0007), CD4þ (P¼ 0.001), CD8þ (P¼0.004), CD3–CD56þ
(P¼0.003), and CD34þ (P¼0.0001) cells were associated with
higher levels of day 28 donor T-cell chimerism. Higher numbers
of CD14þ (P¼0.01) and CD34þ (P¼0.0003) cells were asso-
ciated with rapid achievement of complete donor T-cell
chimerism, while high numbers of CD8þ (P¼0.005) and
CD34þ (P¼ 0.01) cells were associated with low probabilities
of graft rejection. When analyses were restricted to G-PBMC
recipients, higher numbers of grafted CD34þ cells were
associated with higher levels of day 28 donor T-cell chimerism
(P¼0.01), rapid achievement of complete donor T-cell chimer-
ism (P¼0.02), and a trend for lower risk for graft rejection
(P¼0.14). There were no associations between any cell subsets
and acute or chronic GVHD nor relapse/progression. These
data suggest more rapid engraftment of donor T cells and
reduced rejection rates could be achieved by increasing the
doses of CD34þ cells in unrelated grafts administered after
nonmyeloablative conditioning.
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Introduction
To extend allogeneic hematopoietic cell transplantation (HCT)
from unrelated donors (URD) to older patients and those with
comorbid conditions, reduced intensity or truly nonmyeloabla-
tive conditioning regimens have been developed1–6 in which
the burden of tumor eradication has been shifted from the high-
dose chemoradiotherapy agents to cell-based graft-versus-tumor
effects.7 Based on experimental canine studies8 and subsequent
clinical trials in HLA-identical sibling recipients,9 a nonmyeloa-
blative regimen was developed for URD HCT that utilized
minimal host conditioning with fludarabine and 2 Gy total body
irradiation (TBI),5,10,11 combined with postgrafting immunosup-
pression consisting of mycophenolate mofetil (MMF) and
cyclosporine (CSP). We previously reported early data from 89
patients with advanced hematologic malignancies given un-
related grafts after nonmyeloablative conditioning.5 Sustained
engraftment was observed in 60 of 71 (85%) of G-CSF-
mobilized peripheral blood mononuclear cell (G-PBMC) re-
cipients and in 10 of 18 (56%) of marrow recipients.5 Over 40%
of patients with measurable disease at the time of HCT achieved
complete remissions, and 2-year progression-free survival (PFS)
was 42% for G-PBMC recipients.
The focus of the current study was to determine whether the
dose of total nucleated cells (TNC) and/or specific cell subtypes
in the unrelated grafts were associated with clinical outcomes in
130 consecutive patients given unrelated grafts after nonmye-
loablative conditioning for hematologic malignancies. The
eventual aim was to determine whether prospective manipula-
tions of the graft composition might be useful to improve HCT
outcomes in patients with hematologic malignancies given URD
HCT after nonmyeloablative conditioning.
Patients and methods
Patients
Included in the study were results from 130 consecutive patients
with hematologic malignancies given allogeneic HCT after
nonmyeloablative conditioning on prospective research proto-
cols between January 2000 and December 2003 at the Fred
Hutchinson Cancer Research Center (FHCRC), the University of
Washington Medical Center, the Children’s Hospital and
Regional Medical Center and the Veterans Affairs Puget Sound
Health Care System (all in Seattle, WA, USA). Data were
analyzed as of 31 March 2004. The median follow-up for
surviving patients was 531 (range, 93–1475) days. Patients were
considered ineligible for conventional allogeneic HCT because
of age (450 years) and/or comorbidities, or preceding extensive
therapies such as a myeloablative autologous or allogeneic
HCT.5 Reasons for nonmyeloablative conditioning for the 46
patients younger than 50 years (including five patients younger
than 16 years) were previous high-dose myeloablative allo-
geneic (n¼ 3), syngeneic (n¼ 1) or autologous (n¼ 27) HCT,
abnormal liver function tests with or without chronic renal
failure (n¼ 5), cardiomyopathy (n¼ 2), active mycotic infections
(n¼ 2), chronic renal failure (n¼ 1), morbid obesity (n¼ 1),
chronic leg ulcerations (n¼ 1), cavernous arteriovenous mal-
formation (n¼ 1), hypoxemia (n¼ 1), and patient decision
(n¼ 1). Characteristics of the patients are summarized in Table 1.
Median patient age was 54 (range, 5–71) years. Patients were
classified as being at standard-risk, high-risk or very high risk for
disease progression after HCT as described in Table 1.
Pretransplant comorbidities were determined from the patients’
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pretransplant evaluation notes and scored using a template
adapted from the Charlson Comorbidity Index, as previously
reported.12,13
Compatibility between patients and donors for HLA-A, -B,
and -C antigens was assessed by intermediate-resolution DNA
typing to a level at least as sensitive as serology and for -DRB1
and -DQB1 by high-resolution techniques.5 In total, 10 patients
received 1 HLA-antigen-mismatched (three of these also had
single HLA-allele-mismatches) transplants, and 11 had one
HLA-allele-mismatched donors.
Prospective research protocols and the current study were
approved by the Institutional Review Board of the FHCRC for
the participating institutions. All patients signed informed
consents for the original prospective research protocols.
Conditioning regimen, postgrafting
immunosuppression, and HCT collection
All patients were conditioned with fludarabine 30 mg/m2/day on
days 4, 3, and 2, and 2 Gy TBI delivered at 0.07 Gy/min
before URD donor HCT (day 0). Postgrafting immunosuppres-
sion included MMF, 15 mg/kg orally twice a day (n¼ 51)5 or
thrice a day (n¼ 79) from the evening of day 0 until day þ 40,
Table 1 Patients (n¼130)
Characteristic All patients (n¼130) G-PBMC recipients (n¼116)
Median patient age, year (range) 54 (5–71) 54 (9–71)
Recipient gender, #M (%)/#F (%) 85 (65)/45 (35) 74 (64)/42 (36)
Female donor/male recipient, # pts (%) 31 (24) 28 (24)
Diagnosis, # pts (%)
Acute myeloid leukemia 24 (18.5) 20 (17.2)
Acute lymphoblastic leukemia 9 (6.9) 8 (6.9)
Chronic myeloid leukemia 11 (8.5) 10 (8.6)
Chronic lymphocytic leukemia 10 (7.7) 10 (8.6)
Myelodysplastic syndromea 20 (15.4) 17 (14.7)
Multiple myeloma 12 (9.2) 12 (10.3)
Non-Hodgkin’s lymphoma 26 (20.0) 22 (19.0)
Hodgkin’s disease 12 (9.2) 12 (10.3)
Myeloproliferative syndrome other than chronic myeloid leukemia 6 (4.6) 5 (4.3)
Disease risksb, # pts (%)
Standard risk 52 (40.0) 46 (39.7)
High risk 67 (51.5) 61 (52.6)
Very high risk 11 (8.5) 9 (7.7)
Tandem autologous–allogeneic HCT 5 (3.8) 5 (4.3)
Failed previous myeloablative HCT, # pts (%) 51 (39.2) 47 (40.5)
Charlson comorbidity index (CCI)12, # pts (%)
Score 0 59 (45.4) 54 (46.5)
Score 42 18 (13.8) 15 (12.9)
Donor, # pts (%)
HLA-identical 109 (83.8) 96 (82.8)
One HLA antigen-mismatch 10 (7.7) 10 (8.6)
One HLA allele-mismatch 11 (8.5) 10 (8.6)
Stem cell source, # pts (%)
G-PBMC 116 (89.2) 116 (100)
Marrow 14 (10.8) 0
Graft composition, median (range)
Total nucleated cells 909 (153–2958) 966 (235–2958)
CD3+ 247 (16–934) 261 (31–934)
CD4+ 150 (8–586) 155 (20–586)
CD8+ 72 (6–341) 80 (10–341)
CD3–CD56+ 26 (2–68) 27 (11–68)
CD3+CD56+ 14 (1–88) 14 (3–88)
CD20+ 46 (4–184) 48 (26–184)
CD14+ 171 (9–517) 193 (47–517)
CD34+ 6.5 (0.8–26.8) 6.8 (0.8–26.8)
aIncluding patients who received chemotherapy for RAEB, RAEBT, or AML now either in CR or in RA.
bStandard risks were defined as acute myeloid leukemia in first complete remission, acute lymphoblastic leukemia in first complete remission,
myelodysplastic syndrome-refractory anemia, chronic myeloid leukemia in first chronic phase, chronic lymphocytic leukemia, low-grade non-
Hodgkin’s lymphoma, high or intermediate grade non-Hodgkin’s lymphoma in complete remission, Hodgkin’s disease in complete remission,
multiple myeloma in complete remission or with minimal residual disease; very high-risks were defined as acute leukemia above second complete
remission, chronic myeloid leukemia in accelerated phase or blast crisis, and myelodysplastic syndrome-refractory anemia with blast excess or
above; all other diagnoses were classified as high risk.
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and CSP, 6.25 mg/kg orally twice a day from day 3 to day
þ 100. In the absence of GVHD, MMF was tapered at day 40
(day 96 in class 1 HLA-mismatched recipients) over 56 days and
CSP was tapered at day 100 (180 in class 1 HLA-mismatched
recipients) over 180 days.
Donor G-PBMC were generally mobilized using G-CSF
(10 mg/kg/day; day 5 to 1), and collected as per the National
Marrow Donor Program (NMDP) standard for donors collected
in the US (n¼ 96), or according to recommendations from other
National Donor Programs for donors collected outside of the US
(n¼ 20). In total, 10% of the collected G-PBMC were set aside
for cryopreservation for use as DLI, if needed. The remaining
cells were infused intravenously on day 0. In total, 28 patients
(including three children o15 years old) received G-PBMC
obtained in one apheresis collection. No patients were given
product of more than two leukaphereses. In total, 24 liters of
apheresis collection was prescribed by the transplant center
according to HCT protocols, but the decision to perform one or
two collections was at the discretion of the collection centers. A
total of 14 patients received donor marrow harvested by
multiple aspirations from the posterior iliac crests on day 0.
Follow-up
Diagnosis, clinical grading, and treatment of GVHD were
performed as previously reported.5 Standard prophylaxis against
infections was used.5 Patients were examined by a healthcare
provider at least three times a week for the first month and then
at least weekly. Disease-dependent restaging evaluations after
HCT occurred monthly for the first 3 months and then at
6 months, 1 year, and then yearly thereafter.5
Treatment of persistent/progressive or relapsed diseases
and prevention of graft rejection
Progressive or relapsed malignancies in the absence of severe
manifestations of acute and chronic GVHD were treated by
rapid discontinuation of systemic immunosuppression in order
to initiate graft-versus-tumor effects. In addition, three patients
received DLI14 for disease progression, poor T-cell chimerism,
and Epstein–Barr virus-associated lymphoproliferative disease
in donor cells, respectively.
Graft cell subsets enumeration
Enumerations of cell subsets in each graft product were
performed by 3-color analyses using a FACScan cytometer
(Becton Dickinson [BD], San Jose, CA, USA) by the Cellular
Therapy Laboratory at the FHCRC. Samples from grafts were
stained with monoclonal antibodies (all from BD) directed
against the following surface antigens: CD3, CD4, CD8, CD14,
CD20, CD34, and CD56. At least 100 000 events were acquired
per sample. Gates were set around forward vs side scatter and
low 7-amino-actinomycin D staining to include only viable
nucleated cells for further analysis. Cell types were defined as
follows: CD3þ T cell (CD3þCD56–), CD4þ T cell
(CD3þCD4þ ), CD8þ T cell (CD3þCD8þ ), natural killer (NK)
cell (CD3–CD56þ ), NK/T cell (CD3þCD56þ ), B cell (CD19þ ),
monocyte (CD14þ ), and CD34 cells (CD34þCD14–). List mode
data were analyzed with either WinList (Verity Software House
Inc., Topsham, ME, USA) or CellQuest (BD) software to
determine percentages of cell types. Percentages were multi-
plied by the TNC counts of the grafts, determined by use of
an NE8000 Sysmex (TOA Kobe, Japan) automated cell counter,
and volume infused to determine absolute cell numbers, and
divided by actual recipient weight in order to determine cell
doses per kg.
T-cell chimerism analyses
For T-cell chimerism analyses, T cells were isolated from the
peripheral blood by flow cytometry using a Vantage SE
cytometer (BD) on days 28, 56, 84, 180, 365, and then yearly
after HCT. Percentages of donor–host chimerism for recipients
of sex-mismatched HCT were evaluated by fluorescent in situ
hybridization (FISH) for X and Y chromosomes, or by
polymerase chain reaction (PCR)-based amplification of vari-
able-number tandem repeat (VNTR) sequences if patients and
donors were sex-matched.5 Quantification of chimerism using
VNTR was by visual inspection or silver-stained agarose gel with
a standard error of 5%.5
Statistical methods
In order to assess the association of cell-type variables with
outcome, non-cell-type variables were first examined using
regression models and then used to create a base model for each
outcome. The non-cell-type variables used for day 28 T-cell
chimerism levels, cumulative incidence of achieving full donor
chimerism, and risk for graft rejection were prior chemotherapy
or not (agents such as chlorambucil, hydroxyurea, imatinib
mesylate or immunomodulators were classified in the ‘non-
chemotherapy’ group), and tandem autologous/allogeneic HCT.
For acute and chronic GVHD, the non-cell type variables were
patient age, degree of HLA-compatibility, female donor to male
recipient, CMV serostatus, myeloid or lymphoid malignancies,
MMF twice a day vs thrice a day, and Charlson’s comorbidity
index score at transplantation. For overall survival (OS), PFS,
relapse and nonrelapse mortality the non-cell-type variables
were Charlson’s comorbidity index score at transplantation,
disease risk and tandem autologous/allogeneic HCT. Cox
regression models were used for the outcomes of achievement
of full donor T-cell chimerism, relapse/disease progression,
acute and chronic GVHD, PFS, OS, and nonrelapse mortality. A
linear regression model was used for the outcome of day 28 T-
cell chimerism. In all models, cell doses were modeled as
ordinal variables defined by quartile of dose. Means and hazard
ratios thus refer to effects per quartile of dose, and P-values are
interpretable as tests for trend. Spearman rank correlation
coefficient was used to estimate the correlation between cell
types. All P-values are two-sided, and no adjustments were
made for multiple comparisons; thus, values between 0.01 and
0.05 should therefore be considered as suggestive rather than
definitive evidence of a significant association.
Results
Cellular composition of grafts
Table 1 shows the absolute numbers of TNC, CD34þ , CD3þ ,
CD4þ , CD8þ , CD14þ , CD19þ , CD3–CD56þ and
CD3þCD56þ cells contained in the grafts. The correlations
between CD34þ and TNC, CD3þ , CD4þ , CD8þ , CD14þ ,
CD19þ , CD3–CD56þ , and CD3þCD56þ cells were highly
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statistically significant (Po0.0001), but Spearman coefficients
were generally low (Ro0.70). Similarly, the correlations
between CD3þ and CD14þ , CD19þ , CD3–CD56þ and
CD3þCD56þ cells were statistically highly significant
(Po0.0001), and Spearman coefficients were relatively low
(Ro0.70). As expected, the correlations between CD3þ and
CD4þ and CD8þ cells were stronger (R40.85). Among
G-PBMC recipients, graft compositions were not statistically
different among patients who received products from two
leukaphereses in comparison to patients who were given cells
from one leukapheresis. Specifically, among adult G-PBMC
recipients, the mean7s.d. number of CD34þ cells transplanted
was 8.1þ 4.9 106 cells/kg for patients given a 1-apheresis
product, vs 8.2þ 6.4 106 cells/kg for patients given a
2-apheresis product (P¼ 0.95). The number of apheresis
collections was not associated with post-HCT outcomes
(data not shown).
Associations between graft composition and HCT out-
comes in the entire 130 cohort of patients: Day-28 T-cell
chimerism levels were available for 126 of the 130 patients. In
multivariate analyses, high numbers of CD14þ (P¼ 0.0008),
CD3þ (P¼ 0.0007), CD4þ (P¼ 0.001), CD8þ (P¼ 0.004),
CD3–CD56þ (P¼ 0.003), and CD34þ (P¼ 0.0001) cells in
the grafts were associated with high levels of day-28 donor T-
cell chimerism, while high numbers of CD14þ (P¼ 0.01) and
CD34þ (P¼ 0.0003) cells were associated with higher prob-
abilities of achieving full donor chimerism levels in time-
dependent analyses (Table 2). Six of 14 marrow recipients, and
eight of 116 G-PBMC (P¼ 0.001) recipients rejected their grafts.
One of 11 patients given grafts from a one HLA allele
mismatched donor (this patient had CML and was given
marrow) and none of 10 patients given grafts from one HLA
antigen mismatched donors rejected their grafts, compared to 13
of 109 patients (12%) given grafts from 10 of 10 HLA allele-level
matched donors. In multivariate analyses, high numbers of
infused CD8þ (P¼ 0.005) and CD34þ (P¼ 0.01) cells were
associated with lower probabilities of graft rejection. There were
no associations between any cell subsets and acute or chronic
GVHD nor relapse/progression, but there was a trend for better
PFS with higher cell doses transplanted for all cell type
variables, and the association was significant for TNC (HR 0.8
(95% CI, 0.6–0.9), P¼ 0.01). Similarly, there was a trend
for better overall survival with higher cell doses transplanted
for all cell type variables, and the association was significant
for TNC (HR 0.7 (95% CI, 0.5–0.9), P¼ 0.006).
Low day-28 donor T-cell chimerism levels predicted
subsequent graft rejection
Four patients rejected their HCT (o5% donor T-cell chimerism)
before day 28. In the remaining 122 patients studied, day-28
donor T-cell chimerism levels were predictive of the subsequent
risk of graft rejection. Seven of 10 (70%) patients with donor
T-cell chimerism levels between 5–25%, one of eight (13%)
patients with levels between 26 and 50%, two of 17 (12%)
patients with levels between 51 and 75% and 0 of 87 (0%)
patients with levels between 75 and 100% rejected their grafts
(Po0.0001) (Figure 1a).
Table 2 Impact of graft composition on T-cell chimerism and risks of graft rejection among all patients or restricted to G-PBMC recipients
(a) All patients
Day-28 T-cell chimerism Achievement of full donor chimerism (n¼103) Graft rejection (n¼14)
Meana (s.e.) P-valueb HRc (95% CI) P-valueb HRc (95% CI) P-valueb
TNC 4.3 (2.3) 0.07 1.2 (1.0–1.4) 0.08 0.7 (0.4–1.1) 0.13
CD3+ 7.5 (2.1) 0.0007 1.2 (1.0–1.4) 0.04 0.5 (0.3–0.9) 0.02
CD4+ 7.4 (2.2) 0.001 1.3 (1.0–1.5) 0.02 0.6 (0.3–1.0) 0.06
CD8+ 6.4 (2.2) 0.004 1.2 (1.0–1.4) 0.08 0.4 (0.2–0.7) 0.005
CD3–CD56+ 6.9 (2.2) 0.003 1.3 (1.0–1.5) 0.02 0.6 (0.3–1.2) 0.13
CD3+CD56+ 4.9 (2.2) 0.03 1.1 (0.9–1.3) 0.41 0.4 (0.2–0.9) 0.03
CD20+ 2.3 (2.2) 0.31 1.0 (0.9–1.2) 0.82 0.8 (0.5–1.5) 0.55
CD14+ 8.3 (2.4) 0.0008 1.3 (1.1–1.5) 0.01 0.5 (0.3–0.9) 0.03
CD34+ 8.7 (2.2) 0.0001 1.4 (1.2–1.7) 0.0003 0.5 (0.2–0.8) 0.01
(b) G-PBMC recipients
Day-28 T-cell chimerism Achievement of full donor chimerism (n¼97) Graft rejection (n¼ 8)
Meana (s.e.) P-valueb HRc (95% CI) P-valueb HRc (95% CI) P-valueb
TNC 1.5 (2.1) 0.50 1.0 (0.9–1.3) 0.64 1.2 (0.7–2.2) 0.51
CD3+ 4.4 (2.0) 0.03 1.2 (1.0–1.4) 0.09 0.6 (0.3–1.2) 0.15
CD4+ 5.6 (2.0) 0.007 1.2 (1.0–1.4) 0.07 0.7 (0.4–1.4) 0.37
CD8+ 2.2 (2.1) 0.29 1.0 (0.9–1.3) 0.66 0.5 (0.3–1.2) 0.12
CD3–CD56+ 4.3 (2.1) 0.04 1.2 (1.0–1.4) 0.14 0.9 (0.4–2.0) 0.85
CD3+CD56+ 3.2 (2.1) 0.13 1.1 (0.9–1.3) 0.46 0.6 (0.3–1.3) 0.18
CD20+ 0.0 (2.1) 0.99 1.0 (0.8–1.2) 0.75 1.1 (0.6–2.0) 0.84
CD14+ 4.5 (2.3) 0.05 1.2 (1.0–1.4) 0.05 0.8 (0.4–1.7) 0.60
CD34+ 5.2 (2.1) 0.01 1.3 (1.0–1.5) 0.02 0.6 (0.3–1.2) 0.14
TNC¼ total nucleated cells.
aMean chimerism increase per quartile of dose; adjusted for prior chemo or not, and tandem autologous/allogeneic HCT.
bAll P-values were two-sided, and no adjustments were made for multiple comparisons; values between 0.01 and 0.05 should be considered as
suggestive for a difference rather than definitive.
cHR per quartile of dose; adjusted for prior chemo or not, and planned autologous–allogeneic HCT or not.
bold¼ statistically significant.
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Analyses restricted to G-PBMC recipients (n¼ 116)
Associations between graft composition and donor
T-cell engraftment: In multivariate analyses, high numbers
of CD4þ (P¼ 0.007) and CD34þ (P¼ 0.01) cells in the grafts
were associated with high levels of day-28 donor T-cell
chimerism (Table 2). Full donor T-cell chimerism levels (defined
as X95% donor T-cells) were achieved in 97 G-PBMC
recipients between 22 and 105 (median 35) days after HCT. In
multivariate analyses, there was a suggested association
between high number of CD34þ cells and achievement of full
donor chimerism (P¼ 0.02).
Associations between graft composition and graft
rejection: In multivariate analysis, high numbers of infused
CD8þ (HR 0.5, P¼ 0.12) and CD34þ (HR 0.6, P¼ 0.14) cells
were suggestively associated with lower probabilities of graft
rejection, although these associations lacked statistical signifi-
cance, probably as a result of the small number of graft
rejections among G-PBMC recipients (n¼ 8) (Table 2). In
addition, patients given G-PBMC containing more than the
median CD34þ cells dose (6.8 106/kg) had a strong trend for
a lower risk of graft rejection in comparison to patients given
less than the median number of CD34þ cells (HR 0.2 (95% CI,
0.0–1.4, P¼ 0.10)).
Associations between graft composition and graft-
versus-host disease (GVHD): Acute GVHD of grades II,
III, and IV occurred in 64 (55.2%), 16 (13.8%), and 2 (1.7%)
patients, respectively. In multivariate analyses, none of the
cell-type variables were statistically significantly associated
with grades II–IV or III–IV acute GVHD (P-values ranged from
0.48 to 0.98).
Chronic GVHD requiring systemic therapy was seen in 70
patients. In multivariate analyses, none of the cell-type variables
were statistically significantly associated with extensive chronic
GVHD (P-values ranged from 0.12 to 0.69) (Figure 1b and c).
Relapse/progression and nonrelapse mortality: In total,
42 of 116 patients (36%) relapsed/progressed after HCT. Only
one of the 42 patients was given DLI. In the remaining patients,
DLI were contraindicated due to graft rejection (n¼ 5), or
because of GVHD preceding (n¼ 14) or occurring soon after
(n¼ 3) disease progression. Further, DLI was not offered to eight
patients with florid relapse, two patients who relapsedo50 days
after HCT, and five patients with CML (n¼ 2), CLL (n¼ 2) and
MDS, respectively, who achieved complete remissions after
withdrawal of immunosuppression. Finally, two patients refused
DLI, and two patients were given either imatinib or thalidomide
instead of DLI for CML and myeloma relapses, respectively, after
HCT. In multivariate analysis, none of the cell variables was
significantly associated with relapse/progression.
In total, 19 patients (16%) died of nonrelapse causes. In
multivariate analysis, none of the cell variables was significantly
associated with nonrelapse mortality.
Progression-free and overall survival
The probabilities of PFS at 1, 2, and 3 years were 49, 43, and
33%, respectively. In multivariate analyses, there was a trend for
better PFS in patients given higher number of TNC (HR 0.8 (95%
CI, 0.7–1.1), P¼ 0.13), although the association was not
statistically significant.
The probabilities of OS at 1, 2, and 3 years were 62, 52, and
43%, respectively. In multivariate analyses, there was a trend for
better OS in patients given higher number of TNC (HR 0.8 (95%
CI, 0.6–1.0), P¼ 0.06), although the association was not
statistically significant.
Discussion
The present study asked whether the individual cell subsets in
unrelated, unmanipulated hematopoietic grafts affected out-
comes among patients given nonablative conditioning. Our key
findings were as follows. Higher numbers of grafted T-cells
(including CD4þ , CD8þ , and CD3þCD56þ T-cell subsets),
Figure 1 (a) Day-28 T-cell chimerism levels in patients with or
without subsequent graft rejection. Data from patients with graft
rejection before day 28 were not included. Impact of CD34þ (b,
P¼0.36) and CD3þ (c, P¼ 0.52) cells transplanted on cumulative
incidence of chronic extensive graft-versus-host disease among
G-PBMC recipients. The cutpoints for quartile doses were 4.2106,
6.8106, and 12.0 106 CD34þ cells/kg, and 190106, 261 106
and 363 106 CD3þ cells/kg.
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CD14þ cells, NK cells, and CD34þ cells were associated with
higher levels of donor T-cell chimerism, while high CD14þ and
CD34þ contents were associated with more rapid achievement
of complete donor T-cell chimerism, and high T-cell (including
CD8þ and CD3þCD56þ T-cell subsets), monocyte, and
CD34þ cell numbers reduced the risk of graft rejection. Among
T-cell subsets, both CD4þ and CD8þ T cells might promote
T-cell engraftment, confirming previous observations in a canine
model15 and in patients given HCT after myeloablative16,17 or
nonmyeloablative conditioning.18,19 Furthermore, since CD14þ
cells contained in G-PBMC grafts secrete large amounts of IL-10
(an immunosuppressive cytokine) and have reduced expression
of costimulatory molecules needed for T-cell activation, those
cells might provide immunosuppressive effects that reduce
host-versus-graft (rejection) reactions.20
The role of CD3þ cells for the development of acute and
chronic GVHD after allogeneic HCT has been established.16
However, we found no statistical correlation between CD3þ
(including CD4þ and CD8þ subsets) cell doses and the risk of
acute GVHD. This was consistent with previous studies showing
comparable risks of acute GVHD in patients with aplastic
anemia, of whom some did and some did not receive infusions
of viable donor buffy coat cells in addition to marrow grafts after
conditioning with cyclophosphamide.21 Also, several studies
reported similar incidences of acute GVHD after G-PBMC and
marrow grafts despite the infusion of 1 to 2 logs more CD3þ
cells in the G-PBMC inocula.22,23 Perhaps, as suggested by
Kernan et al,24 once an initial threshold (105 CD3þ cells/kg) of
transplanted CD3þ cells has been exceeded, further increases
in T-cell numbers do not necessarily translate into more acute
GVHD for given degrees of genetic disparity between donors
and recipients.
In the current study, higher doses of CD34þ and CD3þ cells
were not associated with increased risks of chronic extensive
GVHD. These results were in agreement with previous
observations in unrelated graft recipients after myeloablative
conditioning,25 but contrasted with findings in related abla-
tive26,27 and nonablative28 recipients that showed a positive
correlation between numbers of CD34þ cells and incidence of
chronic extensive GVHD, and also the finding of a higher
incidence of chronic GVHD in patients with aplastic anemia
given donor buffy coat cells in addition to related marrow
grafts.21 The reasons for the differences among related and
unrelated recipients are unclear. Perhaps, greater disparity for
minor histocompatibility antigens in the unrelated setting could
lead to more chronic GVHD. In addition, it might be that there
were thresholds for CD34þ and CD3þ cell doses above which
correlations between graft composition and chronic GVHD no
longer existed. These thresholds might be lower in unrelated
recipients because of greater minor histocompatibility antigen
divergences than in related recipients.29 However, one recent
study also failed to find a correlation between high CD34þ cell
dose and high incidence of chronic GVHD in patients given
related G-PBMC after nonmyeloablative conditioning.30 The
current observations suggested that there is no upper cell dose
limit for patients given unrelated G-PBMC after nonmyeloa-
blative conditioning with fludarabine and 2 Gy TBI.30
When data from all patients were analyzed, there were trends
for better PFS and OS with higher cell doses for all cell type
variables, and that association was significant for TNC. This
observation agreed with previous reports demonstrating better
PFS in unrelated recipients given higher nucleated cell doses
after myeloablative conditioning.31,32 A similar trend for better
PFS in patients receiving a higher number of TNC was observed
when analyses were restricted to G-PBMC recipients, although
the association was no longer statistically significant. However,
the current study failed to show a correlation between higher
CD8þ cell doses in G-PBMC and better PFS (HR¼ 0.9,
P¼ 0.42) or OS (HR¼ 0.9, P¼ 0.27), as recently proposed by
Cao et al19 in patients given a similar nonmyeloablative
conditioning and postgrafting immunosuppression. That study
analyzed combined observations in 25 patients given G-PBMC
from URD and 38 recipients of related grafts, which may explain
the discrepancy with the current study in unrelated recipients. A
recent study from our group analyzed the impact of graft
composition in 120 patients given G-PBMC from related donors
after nonmyeloablative conditioning, and showed better OS
(P¼ 0.03) in patients given a higher number of CD34þ cells in
the grafts, but no correlations between CD8þ cells contents and
HCT outcomes.30
In conclusion, our data suggested that giving higher doses of
CD34þ cells helped to promote sustained T-cell engraftment in
patients given unrelated grafts after nonmyeloablative condi-
tioning without increasing the risks for acute or chronic GVHD,
and therefore, as many CD34þ cells as possible should be
collected from the donors.
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